Nanoviricides, Inc. · AMEX:NNVC
Nanoviricides — Shareholder Meeting (November 2025)
25 slides from Nanoviricides's shareholder meeting presentation, Nov 8, 2025
Slide 1: NV-387, A Broad-Spectrum Antiviral Presenting A Revolutionary Strategy for Viral Infections
“Bind-Engulf-Destroy” Stock Symbol: NNVC (NYSE American) NV-387, A Broad-Spectrum Antiviral Presenting A Revolutionary Strategy for Viral Infections - Emperic Treatment with NV-387 is Possible Just Like Emperic Treatment of Bacterial Infections Became Possible with Penicillin Anil R. Diwan, PhD, Pre
Slide 2: Disclosure Statement
Disclosure Statement NanoViricides, Inc. is a NYSE-American listed publicly traded company (stock symbol: NNVC). This is not an offering memorandum and should not be construed as such. It is provided as a non-confidential document for informational purposes only. NanoViricides, Inc.(www.nanoviricide
Slide 3: About NanoViricides, Inc.
About NanoViricides, Inc. Founded in USA with Inventors and Inventions in USA Clinical Stage Pharma Company with Unique Nanomedicines Technology NV-387 Successfully Completed Phase I in Healthy Subjects in India Moving to Phase II in DRC to Treat MPox Fully USA-Based On-Shore cGMP Manufacturing of D
Slide 4: Strong Executive Team Independent Board of Directors
Strong Executive Team Anil R. Diwan, PhD Krishna Menon, Meeta R. Vyas, MBA Jayant Tatake, PhD President & Exec. Chairman VMD,MRCS,PhD VP, R&D Consulting Medical Officer CFO Co-Founder 30+ years Experience in Corporate 30+ Years of Pharmaceutical Industry Led Uplisting to NYSE-Amer. in 2013 30+ Years
Slide 5: NanoViricides Drugs Pipeline
NanoViricides Drugs Pipeline - Sustained Commerical Product Development with Benefits for Orphan/Rare Diseases and Pandemic Preparedness Programs Drug Substance Indication Lead Id. Animal Eficacy IND-Enabling Phase I Phase II Phase III Studies 1 MPox India CTA-DRC FDA-ODD, Pre- 2 Smallpox (AOI# 2.3)
Slide 6: Value Proposition of NV-387
Introducing Value Proposition of NV-387-Broad-Spectrum Antiviral NV-387 Emperic Therapy of Viral Infections Made Feasible Some NV-387 Target Product Characteristics TRL 5+ : Phase I Healthy Subjects Completed Successfully NV-387, An SPG-Mimetic Nanoviricide is Designed to Work Against - Oral: NV-387
Slide 7: NanoViricides Platform Technology
NanoViricides Platform Technology => Novel Antiviral Mechanism of Action Schematic Structure Cell-Mimicking Nanomachines that Seek to Bind, Engulf and Destroy a Virus Particle Without Nanoviricide Homopolymer Immune System Assistance Specific Receptor PEG based- RES protection Aqueous Exterior Ligan
Slide 8: POC Mechanism: NV-387 Mechanism is Supported by Different Types of Studies
POC Mechanism: NV-387 Mechanism is Supported by Different Types of Studies 1. A Nanoviricide’s Interaction with a Virus Particle 2. NV-387 Blocks SARS-CoV-2-Pseudovirion in TEM Demonstrates Entry into Human Lung Epithelial Cells, Lipid-Lipid Mixing & Virus Disruption Similar to an Anti-SARS-CoV-2 An
Slide 9: POC In Vivo Broad-Spectrum Activity
POC In Vivo Broad-Spectrum Activity: NV-387 Is Effective in Lethal Animal Models and is Superior/Equivalent to Existing Drugs w No Toxicity Against a Diverse Family of Viruses Virus Family Animal Model Survival Survival Improvement % Survival Improvement NV-387, PO = 14 Days NV-387, PO = 100% Orthop
Slide 10: POC In Vivo Broad-Spectrum: NV-387 Effective Treatment for Measles
POC In Vivo Broad-Spectrum: NV-387 Effective Treatment for Measles - Lung Protection Survival, % Increase in Key Observations Study Id: AE2601 Days Survival Gr Test Article and Lung Cytokine p Lung Viral Overall Dose Strength M F M F Infection Levels: IL4, Plaques Efficacy Histology IL9, IL10 Very M
Slide 11: COVID POC: In Vivo Broad-Spectrum
COVID POC: In Vivo Broad-Spectrum - NV-387 Treatment Caused Significant Viral Load Reduction (2-3 Logs) in Animal Models hCoV NL63: NV-387 Decreased RSV: NV-387 P.O. Decreased Lung Viral Load >3 Logs vs. Vehicle, Day 5. Lung Viral Load >2 Logs vs. Untreated, Day 7. S1: NV-387, PO. 640mg/Kg S2: NV-38
Slide 12: ARDS: Host-Side Effect of NV-387 on Inflammatory Cytokines is Beneficial
ARDS: Host-Side Effect of NV-387 on Inflammatory Cytokines is Beneficial RSV: NV-387 Decreased Inflammatory Cytokines IL-4 and IL-6 by a factor of 4X in BAL © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-mkt: NNVC) Slide 12
Slide 13: ARDS: Host-Side Effect of NV-387 on Inflammatory Cytokines is Beneficial
ARDS: Host-Side Effect of NV-387 on Inflammatory Cytokines is Beneficial Measles: NV-387 Decreased Inflammatory Cytokines IL-4, IL-9 and IL-10 by a factor of 2X in BAL © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-mkt: NNVC) Slide 13
Slide 14: NanoViricides Regulatory Developments
NanoViricides Regulatory Developments NV-387 Clinical Progress Prior US FDA Engagements Two pre-IND Meetings on Two Separate Projects Non-Clinical Studies Completed In 2012-02, for NV-INF-1, an I.V. formulation of a GMP Manufacture of Drug Substance Implemented Sialomimetic nanoviricide for Influenz
Slide 15: NanoViricides Technology Has Significant Advantages Over Current MCM Technologies
NanoViricides Technology Has Significant Advantages Over Current MCM Technologies NV-387 Antibodies Other Drugs Vaccines Antibodies Mechanism Re-Infection Inhibition Neutralization Replication Inhibition Generation Therapeutic Post-Infection? Yes Yes Yes No Viral Resistance? Unlikely Rapidly Eventua
Slide 16: Value Proposition: NanoViricides Technology Offers the Best Feature Matrix
Value Proposition: NanoViricides Technology Offers the Best Feature Matrix NV-387 Antibodies Other Drugs Vaccines Replication Antibodies Mechanism Re-Infection Inhibition Neutralization Inhibition Generation RT ~ 1-2 Years Storage & Supply Chain 2-8°C RT / 2-8°C -20°C Long term: 2-8°C Cost of Drug L
Slide 17: NV-387 for Smallpox Therapeutics
Intro. NV-387 NV-387 for Smallpox Therapeutics for Smallpox NV-387 P.O. is Effective in Ectromelia- SCID-Balb c Mouse - Lethal Infection Target Product Profile Dermal Infection Model, emulate endemic MPox II, Also Smallpox Bioevent NV-387 Oral Gummies (OG) NV-387 at Least Equivalent to Tecovirimat S
Slide 18: Why NV-387 for Smallpox? Currently Approved Smallpox Drugs Fall Short
NV-387 Why NV-387 for Smallpox? Currently Approved Smallpox Drugs Fall Short for Smallpox Drug Tecovirimat Brincidofovir NV-387 Re-Infection Inhibition; Mechanism Eggress Inhibition DNA Polymerase Inhibitor Orthogonal YES, Single-point Higher Bar. But Resistance known for Unlikely (SPG Mimetic Broad
Slide 19: NV-387, PO Improved Survival Equivalent to Tecovirimat
NV-387 NV-387, PO Improved Survival Equivalent to Tecovirimat, in Lethal OrthopoxV, Footpad Intra-digital Ectromelia Infection in SCID Balbc Mouse Model Dermal Infection Study Id AE2301: Survival Data - All Oral Survival, % Increase Test Article, Days in Survival Grp Key Observations Dose Strength M
Slide 20: NV-387, PO Improved Survival Equivalent to Tecovirimat
NV-387 NV-387, PO Improved Survival Equivalent to Tecovirimat, in Lethal OrthopoxV, Intra-Nasal Ectromelia Virus Infection in SCID Balb-c Mice Causing Lung Disease Aerosolic Infection Study Id AE2303: Survival Data - All Oral Survival, % Increase Test Article, Days in Survival Grp Key Observations D
Slide 21: Influenza: NV-387 Survival Substantially Superior to Oseltamivir
Influenza: NV-387 Survival Substantially Superior to Oseltamivir, Peramivir, Baloxavir, in Lethal Lung Influenza A/H3N2 Infection, Balbc Mouse Model, Survival Data Study Id AE1301: Survival Data Test Article, Survival, Days % Survival Increase Grp Key Observations Dose Strength M F M F NV-387-IV Max
Slide 22: NanoViricides Clinical Data and Development Plan for NV-387
NanoViricides Clinical Data and Development Plan for NV-387 Phase I India Healthy Subjects Clinical Data NV-387 Development Plan Timeline Study ID: KM-NV-CoV2-001 (India) (ICH GCP) Phase II Treatment of MPox in DRC under CTA Nov 2025. Dosage - SAD 10, 20, 40 mg/kg NV-387 Oral Syrupp: OR (Outside) AC
Slide 23: NanoViricides Manufacturing is Fully US Based
NanoViricides Manufacturing is Fully US Based NanoViricides GMP Manufacturing Facility NV-387 Manufacturing Multi-Purpose “Pilot-Lab” Type Facility with Movable GMP Drug Substance Manufacture Completed in Scales Reactor Equipment on Chassis. up to 5~10 kg Batch. > 3 Batches. Section I with Air-locks
Slide 24: Intellectual Property
Intellectual Property - NanoViricides Has Complete Freedom to Operate International Patents (PCT) have been filed and issued since 2006 and 2007 on the basic compositions of matter and use for encapsulation, anticancer, antiviral, and All of the intellectual property has been other applications. dev
Slide 25: Nanotechnology-Enabled Targeted Viricides
“Nanotechnology-Enabled Targeted Viricides” A Publicly Traded Company, “NNVC” www.nanoviricides.com Thank you for your attention and guidance. Please address additional inquiries/correspondence to: Scientific and Technical: Business, Finance & Contracts: Together We Can Destroy Viruses Anil R. Diwan